Literature DB >> 9576012

A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses.

C H Chen1, R J Boackle.   

Abstract

A new function for C1 inhibitor (C1 INH) is reported. C1 inhibitor dislodged the entire activated C1 complex (C1qr2s2) from immobilized human IgG. C1 binding to doses of immobilized human IgG3, IgG1, or IgG2 was quantified as a function of time. When human serum, as a source of C1qr2s2, was added to relatively low doses of immobilized IgG, C1q binding peaked at 1.0 min then gradually decreased. However when purified C1q was applied to immobilized IgG, C1q binding did not diminish with time. The removal of C1q was duplicated by adding purified C1 INH to C1qr2s2 which had been bound to immobilized IgG. The dislodgement of C1q from immobilized IgG required the presence of intact C1qr2s2 and of C1 INH. This removal of C1q by purified C1 INH was prevented when activated C1s was used to neutralize C1 INH function or when relatively high levels of IgG were immobilized.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576012     DOI: 10.1006/clin.1997.4515

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

1.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

2.  Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.

Authors:  Hee Young Hwang; Marcus R Duvall; Stephen Tomlinson; Robert J Boackle
Journal:  Mol Immunol       Date:  2008-03-03       Impact factor: 4.407

Review 3.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

4.  C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.

Authors:  C H Chen; C F Lam; R J Boackle
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

5.  Complement 1 inhibitor is a regulator of the alternative complement pathway.

Authors:  H Jiang; E Wagner; H Zhang; M M Frank
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

Review 6.  Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.

Authors:  Saskia Meyer; Jeanette H W Leusen; Peter Boross
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

7.  Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.

Authors:  Satoru Oji; Eva-Maria Nicolussi; Nathalie Kaufmann; Bleranda Zeka; Kathrin Schanda; Kazuo Fujihara; Zsolt Illes; Charlotte Dahle; Markus Reindl; Hans Lassmann; Monika Bradl
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

8.  C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.

Authors:  Seline A Zwarthoff; Kevin Widmer; Annemarie Kuipers; Jürgen Strasser; Maartje Ruyken; Piet C Aerts; Carla J C de Haas; Deniz Ugurlar; Maurits A den Boer; Gestur Vidarsson; Jos A G van Strijp; Piet Gros; Paul W H I Parren; Kok P M van Kessel; Johannes Preiner; Frank J Beurskens; Janine Schuurman; Daniel Ricklin; Suzan H M Rooijakkers
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

9.  Complement susceptibility in glutamine deprived breast cancer cells.

Authors:  Bradley S Ellison; Mary Kb Zanin; Robert J Boackle
Journal:  Cell Div       Date:  2007-07-11       Impact factor: 5.130

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.